Navigation Links
Cancer suppressor gene links metabolism with cellular aging
Date:1/13/2013

PHILADELPHIA - It is perhaps impossible to overstate the importance of the tumor suppressor gene p53. It is the single most frequently mutated gene in human tumors. p53 keeps pre-cancerous cells in check by causing cells, among other things, to become senescent aging at the cellular level. Loss of p53 causes cells to ignore the cellular signals that would normally make mutant or damaged cells die or stop growing.

In short, the p53 pathway is an obvious and attractive target for drug developers. But that strategy has so far proven difficult, as most p53 regulatory proteins operate via protein-protein interactions, which make for poor drug targets, as opposed to ones based on enzymes.

Now, a team of researchers from the Perelman School of Medicine, University of Pennsylvania, has identified a class of p53 target genes and regulatory molecules that represent more promising therapeutic candidates.

As Xiaolu Yang, PhD, professor of Cancer Biology and investigator in Penn's Abramson Family Cancer Research Institute, and his team describe in an advance online Nature publication, p53 participates in a molecular feedback circuit with malic enzymes, thereby showing that p53 activity is also involved in regulating metabolism.(The Yang lab identified p53's role in glucose metabolism in the past.)

The new findings, Yang says, suggest that p53 acts as a molecular sensor of metabolic stress and explains how metabolic stress can lead to senescence in cells.

"We uncovered an important regulatory mechanism for p53 as well as an effector mechanism for p53," Yang says.

Significantly, the findings also identify malic enzymes as novel and potentially useful pharmaceutical targets for anticancer therapy, as well as possible mediators of the normal aging process though neither possibility was actually addressed in the current study.

As cells become damaged and precancerous, the p53 protein prevents those cells from continuing towards becoming tumors by causing the cells to senesce. Metabolic cues also regulate senescence, but the molecular relays coupling those two processes -- senescence and metabolism -- remained unknown.

Yang and his team decided to test if a pair of enzymes, malic enzyme 1 and malic enzyme 2 (ME1 and ME2), could be involved. Malic enzymes recycle malate an intermediate molecule back into an end-product of glycolysis pyruvate storing energy in the process. Malic enzymes are important for adjusting metabolic flux to suit proliferating cells' demands for energy and biosynthesis. Thus, these two enzymes are attuned to the energy and proliferative state of the cell.

Yang's team found that p53 inhibits malic enzyme expression, such that loss of p53 causes malic enzyme abundance to increase. Conversely, malic enzymes keep p53 in check; loss of malic enzymes ramps up p53 activation and induces senescence via either downregulation of a p53 inhibitor (Mdm2) or production of oxygen radicals. Overexpression of malic enzymes inhibits senescence.

The result, Yang explains, is a "feed-forward loop" in which activation of p53 suppresses malic enzyme expression, reducing malic enzyme levels and further upregulating p53, leading to senescence. On the other hand, upregulation of malic enzymes inhibits p53. p53 inhibition loosens the protein's grip on malic enzyme expression, allowing malic enzyme levels to rise.

"This is a circuit," he says. "Going around this loop, you get pretty robust activation."

These same results played out in animal models described in the Nature study. Loss of either ME1 or ME2 reduced tumor weight, even with p53-null tumor cells, which suggests an additional, p53-independent function of malic enzymes.And, overexpression of malic enzymes led to more substantial tumors.

According to Yang, the study pegs malic enzymes as molecular players linking senescence and metabolic state. Those enzymes could potentially serve as anticancer drug targets, he says. But equally important, they may also play a role in the normal process of cellular aging.

"Senescence is aging at the cellular level," says Yang, who notes that considerable research has demonstrated a correlation between caloric restriction and lifespan. "We may have identified a good starting point to understand how aging works."


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related biology news :

1. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
2. Embryonic development protein active in cancer growth
3. BRG1 mutations confer resistance to hormones in lung cancer
4. Genetic variation in East Asians found to explain resistance to cancer drugs
5. Beyond the microscope: Identifying specific cancers using molecular analysis
6. Marshall University study may lead to new treatments for prostate cancer
7. Salk scientists open new window into how cancers override cellular growth controls
8. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
9. Genetic abnormality offers diagnostic hope for childrens cancer
10. Protein jailbreak helps breast cancer cells live
11. Breast cancer risk gene discovery fast tracked by new technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study published in ... previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute ... of blood sampling may improve the value of a blood-based test.” The study ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
Breaking Biology Technology: